2024
Chikungunya Arthritis Treatment with Methotrexate and Dexamethasone: A Randomized, Double-blind, Placebo-controlled Trial
Amaral J, Lucena G, Schoen R. Chikungunya Arthritis Treatment with Methotrexate and Dexamethasone: A Randomized, Double-blind, Placebo-controlled Trial. Current Rheumatology Reviews 2024, 20: 337-346. PMID: 38173199, DOI: 10.2174/0115733971278715231208114037.Peer-Reviewed Original ResearchChronic chikungunya arthritisChikungunya arthritisDouble-blindJoint countPlacebo-controlled clinical trialPain visual analog scalePlacebo-controlled trialChikungunya feverPatient global assessmentVisual analog scaleAffected individualsSwollen joint countTender joint countChikungunya virus infectionDAS28-ESRDexamethasone groupSD ageAnalog scaleBiphasic diseaseTreatment responseClinical trialsAcute phaseDexamethasoneVirus infectionGlobal assessment
2000
Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months
Schoen R, Sikand V, Caldwell M, Van Hoecke C, Gillet M, Buscarino C, Parenti D. Safety and immunogenicity profile of a recombinant outer-surface protein a Lyme disease vaccine: Clinical trial of a 3-dose schedule at 0, 1, and 2 months. Clinical Therapeutics 2000, 22: 315-325. PMID: 10963286, DOI: 10.1016/s0149-2918(00)80035-1.Peer-Reviewed Original ResearchConceptsLyme disease vaccineDisease vaccineThird doseRecombinant outer surface protein A (OspA) vaccineOuter surface protein A (OspA) vaccineRecombinant outer surface proteinGeometric mean antibody titersVaccine 1 monthMost adverse eventsDoses of vaccineMean antibody titersLyme disease endemic areaEnzyme-linked immunosorbentDisease-endemic areasA vaccineAdverse eventsRandomized studyVaccination scheduleImmunogenicity profileSafety profileAntibody titersMonths 0Month 2Clinical trialsEfficacy trials